{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:23:21Z","timestamp":1791440601249,"version":"4.3.3"},"reference-count":31,"publisher":"SAGE Publications","issue":"14","license":[{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["D43TW010540"],"award-info":[{"award-number":["D43TW010540"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:p>Emerging evidence suggests a possible association between hyperglycemia and dolutegravir (DTG), a preferred first-line antiretroviral agent in sub-Saharan Africa (SSA). There is need for rigorous studies to validate this association in the face of increasing DTG use and burden of non-communicable diseases among people living with HIV (PLHIV). We conducted a case\u2013control study to assess the risk of hyperglycemia associated with use of DTG among PLHIV attending Mulago ISS Clinic in Kampala. Cases had hyperglycemia while controls had no hyperglycemia as confirmed by fasting plasma glucose and oral glucose tolerance tests. Demographic, laboratory, and clinical data were collected using interviewer-administered questionnaires and medical record abstraction. Analysis compared cases and controls on DTG use prior to diagnosis of hyperglycemia while controlling for potential confounders using multivariable logistic regression. We included 204 cases and 231 controls. In multivariable analysis, patients with prior DTG use had seven times greater odds of subsequent diagnosis of hyperglycemia compared to those who had non-DTG-based regimens (adjusted odds ratio [aOR] 7.01, 95% CI 1.96\u201325.09). The odds of hyperglycemia also increased with age (56 years and above vs. 18\u201335, aOR 12.38, 95% CI 3.79\u201340.50) and hypertension (aOR 5.78, 95% CI 2.53\u201313.21). Our study demonstrates a strong association between prior DTG exposure and subsequent diagnosis of hyperglycemia. Given the benefits of DTG, wide-scale use, and the growing burden of diabetes mellitus (DM) in SSA, there is need for systematic screening for hyperglycemia and consideration of alternate regimens for those at risk for DM.<\/jats:p>","DOI":"10.1177\/09564624221129410","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T08:41:45Z","timestamp":1665564105000},"page":"1158-1164","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":44,"title":["The risk of hyperglycemia associated with use of dolutegravir among adults living with HIV in Kampala, Uganda: A case-control study"],"prefix":"10.1177","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4413-2745","authenticated-orcid":false,"given":"Daphine","family":"Namara","sequence":"first","affiliation":[{"name":"Uganda Initiative for Integrated Management of Non-Communicable Diseases (UINCD), Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy I","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Uganda Initiative for Integrated Management of Non-Communicable Diseases (UINCD), Kampala, Uganda"},{"name":"Department of General Internal Medicine, Yale University School of Medicine, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew K","family":"Tusubira","sequence":"additional","affiliation":[{"name":"Uganda Initiative for Integrated Management of Non-Communicable Diseases (UINCD), Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4148-5660","authenticated-orcid":false,"given":"Willi","family":"McFarland","sequence":"additional","affiliation":[{"name":"San Francisco Department of Public Health, Center for Public Health Research, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Birungi","sequence":"additional","affiliation":[{"name":"NGO for HIV care, Makerere University Joint AIDS Program (MJAP), Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred C","family":"Semitala","sequence":"additional","affiliation":[{"name":"NGO for HIV care, Makerere University Joint AIDS Program (MJAP), Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Muddu","sequence":"additional","affiliation":[{"name":"NGO for HIV care, Makerere University Joint AIDS Program (MJAP), Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"key":"bibr1-09564624221129410","unstructured":"HIV.gov. The Global HIV\/AIDS Overview. Department of Health and Human Services, https:\/\/www.hiv.gov\/federal-response\/pepfar-global-aids\/global-hiv-aids-overview(2021 (2021, accessed 6 August 2021)."},{"key":"bibr2-09564624221129410","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000298"},{"key":"bibr3-09564624221129410","author":"Casper C","year":"2017","journal-title":"Major Infectious Diseases"},{"key":"bibr4-09564624221129410","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252180"},{"key":"bibr5-09564624221129410","doi-asserted-by":"publisher","DOI":"10.4081\/jphr.2014.99"},{"key":"bibr6-09564624221129410","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221022"},{"key":"bibr7-09564624221129410","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.2000.00083.x"},{"key":"bibr8-09564624221129410","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2902"},{"key":"bibr9-09564624221129410","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2014.06.001"},{"key":"bibr10-09564624221129410","unstructured":"National Institute of Allergy and Infectious Diseases. Antiretroviral drug discovery and development. National Institutes of Health, https:\/\/www.niaid.nih.gov\/diseases-conditions\/antiretroviral-drug-development (2018, accessed 6 August 2021)."},{"key":"bibr11-09564624221129410","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30400-X"},{"key":"bibr12-09564624221129410","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(16)30091-1"},{"key":"bibr13-09564624221129410","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02104-18"},{"key":"bibr14-09564624221129410","volume-title":"Policy brief: update of recommendations on first- and second-line antiretroviral regimens","author":"World Health Organization","year":"2019"},{"key":"bibr15-09564624221129410","unstructured":"Ministry of Health, Uganda. Consolidated guidelines for the prevention and treatment of HIV and AIDS in Uganda, https:\/\/elearning.idi.co.ug\/pluginfile.php\/5675\/mod_page\/content\/24\/Consolidated%20HIV%20and%20AIDS%20Guidelines%202020%20June%2030th.pdf (2020, accessed 6 August 2021)."},{"key":"bibr16-09564624221129410","doi-asserted-by":"crossref","unstructured":"Granich R, Gupta S, Kosicki L, et al. Dolutegravir and the universal antiretroviral regimen: Good may be the enemy of perfect [WEAD0304]. In: Presented at: 22nd International AIDS Conference, Amsterdam, Netherlands, 2018.","DOI":"10.1016\/S2055-6640(20)30373-3"},{"key":"bibr17-09564624221129410","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx365"},{"key":"bibr18-09564624221129410","doi-asserted-by":"publisher","DOI":"10.2147\/IMCRJ.S323233"},{"issue":"10","key":"bibr19-09564624221129410","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1097\/QAD.0000000000002930","volume":"35","author":"McCann K","year":"2021","journal-title":"AIDS"},{"key":"bibr20-09564624221129410","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30042-4"},{"key":"bibr21-09564624221129410","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025236"},{"key":"bibr22-09564624221129410","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/396505"},{"key":"bibr23-09564624221129410","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-S002"},{"key":"bibr24-09564624221129410","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S002"},{"key":"bibr25-09564624221129410","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.191227"},{"key":"bibr26-09564624221129410","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz360.418"},{"key":"bibr27-09564624221129410","unstructured":"Cogliandro1 V., Lapadula1 G., Squillace1 N., et al. New cases of diabetes dolutegravir-associated in HIV patients: a case series(P117). In: Presented at: 12th National Conference ICAR Italian Conference on AIDS and Antiviral Research, Riccione, Italy, 2020."},{"key":"bibr28-09564624221129410","doi-asserted-by":"publisher","DOI":"10.1210\/js.2019-SUN-187"},{"key":"bibr29-09564624221129410","doi-asserted-by":"publisher","DOI":"10.4103\/jod.jod_50_18"},{"key":"bibr30-09564624221129410","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3221-7"},{"key":"bibr31-09564624221129410","doi-asserted-by":"publisher","DOI":"10.1186\/s40200-017-0310-x"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624221129410","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09564624221129410","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624221129410","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:43:52Z","timestamp":1777675432000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09564624221129410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":31,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1177\/09564624221129410"],"URL":"https:\/\/doi.org\/10.1177\/09564624221129410","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,12]]}}}